Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. ("Spectral" or the "Company") (TSX:EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial. Under the terms of the Company's Exclusive Distribution Agreement with Baxter International ("Baxter") (NYSE:BAX), at Interim Enrollment, Baxter has the option to make a second milestone payment to Spect ...